Cyclerion Therapeutics Inc
CYCN1.690USD
-0.170-9.14%
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
5.20MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cyclerion Therapeutics Inc Unternehmen
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Cyclerion Therapeutics Inc Informationen
BörsenkürzelCYCN
Name des UnternehmensCyclerion Therapeutics Inc
IPO-datumMar 18, 2019
CEODr. Regina M. Graul, Ph.D.
Anzahl der mitarbeiter1
WertpapierartOrdinary Share
GeschäftsjahresendeMar 18
Addresse301 Binney Street
StadtCAMBRIDGE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02142
Telefon16176217722
Websitehttps://www.cyclerion.com/
BörsenkürzelCYCN
IPO-datumMar 18, 2019
CEODr. Regina M. Graul, Ph.D.
Führungskräfte von Cyclerion Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Hecht (Peter M)
16.76%
J. Wood Capital Advisors LLC
5.45%
Tyndall Management, LLC
4.65%
American Endowment Foundation
3.99%
Invus Public Equities Advisors, LLC
3.48%
Andere
65.68%
Aktionäre
Aktionäre
Anteil
Hecht (Peter M)
16.76%
J. Wood Capital Advisors LLC
5.45%
Tyndall Management, LLC
4.65%
American Endowment Foundation
3.99%
Invus Public Equities Advisors, LLC
3.48%
Andere
65.68%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
22.05%
Corporation
9.43%
Investment Advisor
5.69%
Investment Advisor/Hedge Fund
5.63%
Hedge Fund
0.08%
Research Firm
0.03%
Andere
57.09%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
33
381.61K
11.43%
-552.00K
2025Q2
47
1.50M
44.80%
-242.81K
2025Q1
64
1.40M
44.62%
-170.60K
2024Q4
68
1.21M
44.74%
-507.00K
2024Q3
71
1.75M
64.88%
-8.65K
2024Q2
75
1.75M
64.62%
-27.65K
2024Q1
84
1.73M
66.48%
-9.21K
2023Q4
93
1.67M
68.18%
-15.51K
2023Q3
103
1.45M
60.44%
-312.49K
2023Q2
122
1.38M
57.36%
-283.95K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Hecht (Peter M)
559.20K
16.76%
--
--
Apr 21, 2025
J. Wood Capital Advisors LLC
181.82K
5.45%
+181.82K
--
Apr 21, 2025
Tyndall Management, LLC
155.19K
4.65%
-9.59K
-5.82%
Jun 30, 2025
American Endowment Foundation
133.03K
3.99%
+133.03K
--
Dec 31, 2024
Invus Public Equities Advisors, LLC
116.16K
3.48%
--
--
Jun 30, 2025
Graul (Regina Margaret)
55.78K
1.67%
-44.52K
-44.39%
Apr 21, 2025
De Souza (Errol B)
50.00K
1.5%
--
--
Apr 21, 2025
Geode Capital Management, L.L.C.
32.73K
0.98%
+1.13K
+3.58%
Jun 30, 2025
Higgins (Michael J)
30.74K
0.92%
+1.65K
+5.67%
Apr 21, 2025
The Vanguard Group, Inc.
23.49K
0.7%
--
--
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
Datum
Art
Verhältnis
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
